Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Long-Term Debt Repayments (2022 - 2025)

SAB Biotherapeutics' Long-Term Debt Repayments history spans 4 years, with the latest figure at $3.0 for Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments fell 100.0% year-over-year to $3.0; the TTM value through Dec 2025 reached $275849.0, down 78.63%, while the annual FY2025 figure was $275849.0, 78.63% down from the prior year.
  • Long-Term Debt Repayments reached $3.0 in Q3 2025 per SABSW's latest filing, down from $138551.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $761050.0 in Q2 2022 to a low of $3.0 in Q3 2025.
  • Average Long-Term Debt Repayments over 4 years is $323711.2, with a median of $254913.0 recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: soared 450.36% in 2024, then tumbled 100.0% in 2025.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $488437.0 in 2022, then crashed by 47.59% to $255989.0 in 2023, then dropped by 6.19% to $240133.0 in 2024, then crashed by 100.0% to $3.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Long-Term Debt Repayments are $3.0 (Q3 2025), $138551.0 (Q2 2025), and $137295.0 (Q1 2025).